Zymeworks (ZYME) Leerink Global Healthcare Conference 2026 summary

Strategic evolution and capital deployment

• Focus has shifted to R&D and partnerships, leveraging expertise in ADCs, T-cell engagers, and protein engineering, with less emphasis on direct commercialization or late-stage development.

• Capital from royalties and milestones, notably from Jazz and BeiGene, is allocated across internal pipeline development, asset aggregation/business development, and share buybacks.

• $120 million in stock buybacks authorized, with $62 million implemented, following $80 million in buybacks the previous year.

• Asset aggregation strategy involves acquiring and developing external assets using internal R&D capabilities to maximize value and future partnerships.

• Recent $250 million debt financing with Royalty Pharma allows retention of 70% of royalties, with full royalty rights returning after repayment, providing low-cost capital for further investment.

Pipeline highlights and clinical progress

• Zanidatamab (Zani) demonstrated positive phase III results in gastric/GEA cancer, with improved PFS and OS, and is expected to change the standard of care; U.S. approval anticipated in late 2026.

• Zani is also being evaluated in breast cancer, with phase III trials enrolling faster than expected and potential to address post-Enhertu settings.

• Internal ADC pipeline includes a best-in-class folate receptor alpha ADC in dose optimization and a GPC3 ADC in phase I, both leveraging proprietary antibody and payload technologies.

• Tri-specific T-cell engager targeting DLL3 for small cell lung cancer is set to enter the clinic, with additional preclinical ADCs and T-cell engagers in development.

• KLK2 T-cell engager, licensed to J&J, is in three registration trials for advanced prostate cancer, reflecting strong partner enthusiasm and clinical momentum.

Business model and partnership approach

• Capital allocation decisions are made based on comparative return versus existing royalty streams, with flexibility to out-license at various development stages depending on asset and market dynamics.

• Internal R&D and business development teams are central to diligence, acquisition, and development of assets, differentiating from traditional royalty shops.

• Partnerships with major pharma (Jazz, J&J) validate platforms and provide substantial future royalties, supporting ongoing innovation and portfolio expansion.